IMR Press / FBL / Volume 24 / Issue 8 / DOI: 10.2741/4788

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Article
miR-21 regulates growth and EMT in lung cancer cells via PTEN/Akt/GSK3β signaling
Show Less
1 Department of Emergency, Shidong Hospital of Yangpu District, Shanghai 200438, China
2 Department of Respiratory Medicine, Shidong Hospital of Yangpu District, Shanghai 200438, China
3 Department of Respiratory Medicine, Jinshan Tinglin Hospital, Shanghai, 201505, China
4 Department of Respiratory Medicine, Huashan Hospital, Fudan University, Shanghai, 200000, China
5 Cellular and Molecular Biology and Histology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
6 Materno-Fetal Assistance Excellence Unit, Alessandrescu-Rusescu National Institute of Mother and Child Health, Bucharest, Romania (Dragos Cretoiu)
Front. Biosci. (Landmark Ed) 2019, 24(8), 1426–1439;
Published: 1 June 2019
(This article belongs to the Special Issue Leader sequences of coronavirus are altered during infection)

miRNA-21 (miR-21) is overexpressed in various human cancers. Here, we show that miR-21 is overexpressed in human Non-Small Cell Lung Cancer (NSCLC) and that its up or down-regulation, respectively, increases or decreases cyclin D1 and cyclin E1 expression and coordinately promotes or inhibits proliferation of cancer cells. The perturbations of miR-21 also dramatically reduces or increases epithelial to mesenschymal transition (EMT). We show that regulation of proliferation and EMT are directed by PTEN/Akt/GSK3 beta signaling axis by regulating the expression of invasion markers including E-cadherin, vimentin, snail, slug and beta-catenin. Together, these findings show that miR-21 is a potential target for the development of treatment for NSCLC forms of human lung cancer.

Micro RNA-21
Lung cancer
Figure 1.
Back to top